Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100-Reference-Cited by-同舟云学术

Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100

Published:2022-02-21 Issue:5 Volume:36 Page:1429-1431
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Visram Alissa^ORCID,Rajkumar S. Vincent,Kapoor Prashant^ORCID,Dispenzieri Angela^ORCID,Lacy Martha Q.,Gertz Morie A.,Buadi Francis K.^ORCID,Hayman Suzanne R.,Dingli David^ORCID,Kourelis Taxiarchis^ORCID,Gonsalves Wilson,Warsame Rahma,Muchtar Eli^ORCID,Leung Nelson^ORCID,Kyle Robert A.,Kumar Shaji K.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-022-01529-w.pdf

Reference11 articles.

1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.

2. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27:941–6.

3. Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia. 2013;27:947–53.

4. Fonseca R, Gonzalez-Velez M. Treatment of smoldering multiple myeloma: expectant observation should still be the standard. Am Soci Clin Oncol Educ Book. 2020;40:364–70.

5. Abraham RS, Charlesworth MC, Owen BA, Benson LM, Katzmann JA, Reeder CB, et al. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin Chem. 2002;48:1805–11.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How to Identify and Manage High-Risk Smoldering Multiple Myeloma;Current Oncology Reports;2024-08-23

2. The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR);British Journal of Haematology;2024-07-04

3. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-06-28

4. The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management;Cancers;2024-06-19

5. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma;Blood Cancer Discovery;2024-05-01